Prokaryotics Scientific Advisory Board is made up of some of the world’s leading experts in the field of antibacterial drug discovery and development.
Thomas J. Silhavy, PhD
Dr. Silhavy is the Warner-Lambert Parke-Davis Professor of Molecular Biology at Princeton University. His area of expertise includes the bacterial genetics of Gram-negative cell envelope biogenesis.
Dr. Robert A. Bonomo, MD
Dr. Bonomo is Distinguished University Professor of Medicine, Pharmacology, Molecular Biology and Microbiology at Case Western Reserve University and Director of the Case VA Center for Antimicrobial Resistance and Epidemiology. He brings 30+ years of experience in clinical medicine and the study of how Gram-negative bacteria evolve multidrug-resistance.
Lynn Silver, PhD
Dr. Silver is a recognized Thought Leader and Consultant in Antibacterial Discovery with over 30 years of experience, including a long and successful career at Merck, and over 70 peer reviewed and frequently cited publications.
Richard Lee, PhD
Dr. Lee is a Member and Endowed Chair of Medicinal Chemistry at St. Jude Children’s Research Hospital, and an expert in Antibacterial Chemistry and Structure Based Drug Design.
David Perlin, PhD
Dr. Perlin is Chief Scientific Officer and Senior Vice-President of the Center for Discovery and Innovation and Professor of Medical Sciences at the Hackensack Meridian School of Medicine at Seton Hall University. His research emphasizes studies to diagnose and overcome drug-resistant fungal and bacterial infections by exploiting insights obtained from molecular investigations of drug resistance, pathogenicity, and host response to improve current therapies and develop novel drugs and diagnostics.
John Tomayko, MD
Dr. Tomayko is Vice President of Clinical Development at F2G, and is an expert in the Clinical Development of antibiotics with extensive experience in industry in key roles at Pfizer, Spero and GSK.
David Pompliano, PhD
Dr. Pompliano is currently Operating Partner at Accelerator Life Science Partners, and has had a long and influential career in Infectious Disease Drug Discovery in a variety of roles, including VP at Merck, CSO at Revolution Medicines and Lodo Therapeutics, and entrepreneur at Third Rock Ventures.
Gerry Wright, PhD
Dr. Wright is Distinguished University Professor and Canada Research Chair in Antibiotic Biochemistry at McMaster University, and has over 30 years of experience in antibiotic resistance and discovery research.